38 reports

  • Global Tuberculosis (TB) Drugs Market is Expected to Grow to $1,035.67 mn by 2021
  • 2.1 Preface
  • Pathology
  • Tuberculosis
  • World
  • Forecast
  • Sandoz Inc.

Individual majorly suffer from two predominant forms of TB: Active tuberculosis and Latent tuberculosis.

  • Tuberculosis
  • Asia
  • North America
  • World
  • Forecast
  • 35% of the market share comes from culture
  • OVERVIEW
  • Tuberculosis
  • Forecast
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.

Global R& D spending on Tuberculosis ##. ##.

  • Pathology
  • Tuberculosis
  • World
  • Tuberculosis Treatment Drugs Market Overview
  • Top 10 Tuberculosis Drugs Sales Volume and Their
  • Tuberculosis
  • China
  • Demand
  • Trade
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Profiles of Tuberculosis Drugs Producers
  • Top 10 Tuberculosis Drugs Sales Volume and Their
  • Tuberculosis
  • China
  • Demand
  • Market Size
  • Shandong Lukang Pharmaceutical Co., Ltd

Based on Therapeutics the market is categorized into Tuberculosis Drugs (First Line) and Tuberculosis Drugs (Second Line).

  • Therapy
  • Tuberculosis
  • United States
  • World
  • Forecast
  • Profiles of Tuberculosis Drugs Producers
  • CHAPTER VII TUBERCULOSIS DRUGS PRODUCER DIRECTORY
  • Tuberculosis
  • China
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shenyang Shuangding Pharmaceutical Co., Ltd.
  • Epistem Holdings Plc Pipeline Products by Indication
  • Oct 28, 2014: Successful completion of Genedrive Indian clinical trials and regulatory submission
  • Tuberculosis
  • India
  • World
  • Epistem Holdings Plc
  • GlobalData's company

Tuberculosis Diagnostics Market Size And Forecast By Test Types And Trend Analysis From 2013 to 2024 Table of Content Chapter ## Research Methodology ##. ## Research Methodology ##. ## Research Scope & Assumptions ##. ## List of Data Sources Chapter ## Executive Summary Chapter ## Market Summary Ch

  • Diagnostics
  • Laboratory
  • Pathology
  • Tuberculosis
  • Market Size
  • Peptides for Tuberculosis
  • TUBERCULOSIS - PIPELINE BY GLAXOSMITHKLINE PLC, H1 2017
  • DNA
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULES TO INHIBIT DNA GYRB FOR TUBERCULOSIS
  • PIPELINE BY ASTRAZENECA PLC, H2 2017
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
  • Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • TUBERCULOSIS VACCINE - DRUG PROFILE
  • TUBERCULOSIS VACCINE - DRUG PROFILE
  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis
  • Pipeline by Johnson & Johnson, H2 2016
  • Antibiotic Resistance
  • Tuberculosis
  • World
  • Product Initiative
  • Lycera Corp.
  • tuberculosis vaccine - Drug Profile
  • Mycobacterium tuberculosis Protein Ag85A Overview
  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative
  • 8.2 TUBERCULOSIS
  • THE TUBERCULOSIS DISEASE SEGMENT TO DOMINATE THE RESPIRATORY
  • Diagnostics
  • Hospital
  • Tuberculosis
  • Market Size
  • Alere Inc.
  • Pulmonary Tuberculosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Pulmonary Tuberculosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Product Initiative
  • TUBERCULOSIS VACCINE
  • DELAMANID
  • Research And Development
  • Tuberculosis
  • World
  • Product Initiative
  • TB Drug Development, Inc.
  • MBIO DIAGNOSTIC ASSAY - TUBERCULOSIS - PRODUCT DESCRIPTION
  • MBIO DIAGNOSTIC ASSAY - TUBERCULOSIS - PRODUCT STATUS
  • Diagnostics
  • Tuberculosis
  • United States
  • Company
  • MBio Diagnostics, Inc.
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS
  • NOVARTIS ENTERS INTO LICENSING AGREEMENT WITH GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT FOR TUBERCULOSIS DRUGS
  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • World
  • TB Drug Development, Inc.
  • Official Title
  • Tuberculosis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • TB Drug Development, Inc.

Tuberculosis Vaccine ## Aeras Enters Into Co-Development Agreement With Infectious Disease Research Institute For ID##/ GLA-SE ## Aeras Enters Into Co-Development Agreement With Tianjin CanSino For Tuberculosis Vaccine ## Aeras Enters Into Co-Development Agreement With China

  • Pathology
  • Tuberculosis
  • Vaccine
  • World
  • M&A
  • PARTNERSHIPS

We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world. "

  • Pathology
  • Tuberculosis
  • China
  • Corporate Finance
  • GlobalData's company
  • JAN 07, 2016: USAID AND CEPHEID PLAN COLLABORATION TO ACCELERATE GLOBAL DIAGNOSIS OF MULTIDRUG-RESISTANT TUBERCULOSIS
  • JAN 07, 2016: USAID AND CEPHEID PLAN COLLABORATION TO ACCELERATE GLOBAL DIAGNOSIS OF MULTIDRUG-RESISTANT TUBERCULOSIS
  • Medical Supply
  • Tuberculosis
  • United States
  • Company Financials
  • Cepheid
  • Application
  • Application
  • Genomics
  • Tuberculosis
  • United States
  • Product Initiative
  • GlobalData's company
  • Application
  • Application
  • Genomics
  • Tuberculosis
  • United States
  • Product Initiative
  • GlobalData's company
  • Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203
  • Qurient Raises USD25.7 Million in IPO
  • Healthcare
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.
  • JANSSEN PHARMA ENTERS INTO AGREEMENT WITH FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH CEPHEID AND RUTGERS

The agreement enables FIND, Cepheid and Rutgers to develop next-generation test for mycobacterium tuberculosis.

  • Diagnostics
  • Pharmaceutical
  • Tuberculosis
  • United States
  • GlobalData's company
  • Anacor Pharmaceuticals, Inc. - Discovery, 2016
  • Pharmaceutical
  • Tuberculosis
  • World
  • Product Initiative
  • Anacor Pharmaceuticals, Inc.